No Data
Sinolink: Focus on innovative growth in pharmaceutical investment for 2025, with a dual approach of "AI + Innovative Drugs."
In traditional medicine, policy expectations are anticipated to reverse and performance pressure may soon show a turnaround. Seize the opportunities of Innovative Drugs expanding overseas and the increased volume in the domestic market, as well as the recovery opportunities in the left-side Sector stocks.
Sinolink: The rising enthusiasm for HEALTH CARE A applications is worth investing in; the traditional main line may welcome a reversal in the quarterly reports.
With the development and progress of AI technology, AI continuously makes new advancements in empowering medical and healthcare, promoting industry upgrades, and its application in the medical and health field is expected to enter an accelerated development stage.
Does Yifeng Pharmacy Chain (SHSE:603939) Have A Healthy Balance Sheet?
Yifeng Pharmacy Chain (603939.SH): Gao Youcheng and Yan Jun plan to collectively reduce their shareholding by no more than 0.0753 million shares.
Gelonghui, January 23 – Yifeng Pharmacy Chain (603939.SH) announced that Mr. Gao Youcheng and Mr. Yan Jun plan to reduce their shareholding in the company through centralized bidding due to their own funding needs. Mr. Gao Youcheng will reduce his holding by no more than 50,400 shares, and Mr. Yan Jun will reduce his holding by no more than 24,900 shares. The total number of shares to be reduced will not exceed 75,300 shares, with each reduction not exceeding 25% of their held shares in the company. The reduction will be carried out within three months after fifteen trading days from the date of this announcement, with the reduction price determined by the market price at the time of the reduction.
Two executives of Yifeng Pharmacy Chain (603939.SH) plan to collectively reduce their shareholding by no more than 0.0753 million shares.
Yifeng Pharmacy Chain (603939.SH) announced that Mr. Gao Youcheng and Mr. Yan Jun plan to transfer...
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Returns Are Gaining Momentum At Yifeng Pharmacy Chain (SHSE:603939)
